• About Us
    • Our Company
    • Management Team
    • Board of Directors
    • Clinical Advisory Board
  • Product Candidates
  • Recent News
    • Press Releases
    • Research + Whitepapers
    • News
  • Contact Us

News

News

Scientists behind LANCL2 target launch with phase III-ready drug

By NImmune Biopharma | Jun 23, 2023

Many of the available treatments for the autoimmune conditions ulcerative colitis (UC) and Crohn’s disease come with drawbacks such as safety issues or inconvenient dosing regimens. Describing itself as a biomarker-driven immunoregulatory therapeutics company,...

Read More

News

NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

By NImmune Biopharma | Mar 22, 2023

Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis. NImmune Biopharma’s lead asset...

Read More

  • About Us
  • Management Team
  • Board of Directors
  • Clinical Advisory Board
  • Product Candidates
  • Contact Us

Copyright © 2024 NImmune Biopharma